

# James L Riley

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2901491/publications.pdf>

Version: 2024-02-01

129  
papers

21,861  
citations

13099

68  
h-index

15732

125  
g-index

130  
all docs

130  
docs citations

130  
times ranked

23523  
citing authors

#	ARTICLE	IF	CITATIONS
1	CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms. <i>Molecular and Cellular Biology</i> , 2005, 25, 9543-9553.	2.3	1,609
2	The CD28 Signaling Pathway Regulates Glucose Metabolism. <i>Immunity</i> , 2002, 16, 769-777.	14.3	1,201
3	SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation. <i>Journal of Immunology</i> , 2004, 173, 945-954.	0.8	989
4	Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo. <i>Molecular Therapy</i> , 2009, 17, 1453-1464.	8.2	988
5	Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. <i>Nature Biotechnology</i> , 2008, 26, 808-816.	17.5	916
6	Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 3360-3365.	7.1	758
7	PD-1 signaling in primary T cells. <i>Immunological Reviews</i> , 2009, 229, 114-125.	6.0	655
8	Cutting Edge: Regulatory T Cells from Lung Cancer Patients Directly Inhibit Autologous T Cell Proliferation. <i>Journal of Immunology</i> , 2002, 168, 4272-4276.	0.8	652
9	Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells. <i>Science Translational Medicine</i> , 2012, 4, 132ra53.	12.4	555
10	Identification of a Titin-Derived HLA-A1*Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3-Directed T Cells. <i>Science Translational Medicine</i> , 2013, 5, 197ra103.	12.4	539
11	Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor. <i>Clinical Cancer Research</i> , 2011, 17, 4719-4730.	7.0	441
12	Human T Regulatory Cell Therapy: Take a Billion or So and Call Me in the Morning. <i>Immunity</i> , 2009, 30, 656-665.	14.3	400
13	Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. <i>Nature Biotechnology</i> , 2002, 20, 143-148.	17.5	395
14	FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 4571-4576.	7.1	370
15	The PDL1-PD1 Axis Converts Human T <sub>H</sub> 1 Cells into Regulatory T Cells. <i>Science Translational Medicine</i> , 2011, 3, 111ra120.	12.4	370
16	Chronic Virus Infection Enforces Demethylation of the Locus that Encodes PD-1 in Antigen-Specific CD8+ T Cells. <i>Immunity</i> , 2011, 35, 400-412.	14.3	357
17	Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor-Directed Human T cells in Solid Tumors. <i>Clinical Cancer Research</i> , 2014, 20, 4262-4273.	7.0	339
18	DC-SIGN and DC-SIGNR Bind Ebola Glycoproteins and Enhance Infection of Macrophages and Endothelial Cells. <i>Virology</i> , 2003, 305, 115-123.	2.4	338

#	ARTICLE	IF	CITATIONS
19	Umbilical cord bloodâ€‘derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. Blood, 2016, 127, 1044-1051.	1.4	333
20	Role of PD-1 during effector CD8 T cell differentiation. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 4749-4754.	7.1	327
21	Massive ex Vivo Expansion of Human Natural Regulatory T Cells (T <sub>regs</sub> ) with Minimal Loss of in Vivo Functional Activity. Science Translational Medicine, 2011, 3, 83ra41.	12.4	326
22	Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 11790-11795.	7.1	279
23	The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. Blood, 2005, 105, 13-21.	1.4	276
24	CD25 Blockade Depletes and Selectively Reprograms Regulatory T Cells in Concert with Immunotherapy in Cancer Patients. Science Translational Medicine, 2012, 4, 134ra62.	12.4	264
25	Strength of PD-1 signaling differentially affects T-cell effector functions. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E2480-9.	7.1	242
26	Engineering Artificial Antigen-presenting Cells to Express a Diverse Array of Co-stimulatory Molecules. Molecular Therapy, 2007, 15, 981-988.	8.2	236
27	Clinical Grade Manufacturing of Human Alloantigen-Reactive Regulatory T Cells for Use in Transplantation. American Journal of Transplantation, 2013, 13, 3010-3020.	4.7	226
28	Antiviral Effect and Ex Vivo CD4+ T Cell Proliferation in HIV-Positive Patients as a Result of CD28 Costimulation. Science, 1996, 272, 1939-1943.	12.6	224
29	Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nature Medicine, 2008, 14, 1390-1395.	30.7	224
30	The Inducible Costimulator (ICOS) Is Critical for the Development of Human T <sub>H</sub> 17 Cells. Science Translational Medicine, 2010, 2, 55ra78.	12.4	221
31	Differential Regulation of HIV-1 Fusion Cofactor Expression by CD28 Costimulation of CD4+ T Cells. Science, 1997, 276, 273-276.	12.6	206
32	Generation and Large-Scale Expansion of Human Inducible Regulatory T Cells That Suppress Graft-Versus-Host Disease. American Journal of Transplantation, 2011, 11, 1148-1157.	4.7	192
33	Cd40 Ligand (Cd154) Triggers a Short-Term Cd4+ T Cell Activation Response That Results in Secretion of Immunomodulatory Cytokines and Apoptosis. Journal of Experimental Medicine, 2000, 191, 651-660.	8.5	185
34	Engineering lymphocyte subsets: tools, trials and tribulations. Nature Reviews Immunology, 2009, 9, 704-716.	22.7	185
35	Repression of the genome organizer SATB1 in regulatory T cells is required for suppressive function and inhibition of effector differentiation. Nature Immunology, 2011, 12, 898-907.	14.5	179
36	Activation of class II MHC genes requires both the X <sup>3</sup> -region and the class II transactivator (CIITA). Immunity, 1995, 2, 533-543.	14.3	176

#	ARTICLE	IF	CITATIONS
37	CAR T cells for infection, autoimmunity and allotransplantation. <i>Nature Reviews Immunology</i> , 2018, 18, 605-616.	22.7	173
38	PSMA-targeting TGF $\beta$ -insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. <i>Nature Medicine</i> , 2022, 28, 724-734.	30.7	171
39	Constitutive cell surface association between CD4 and CCR5. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999, 96, 7496-7501.	7.1	169
40	Cutting Edge: Foxp3-Mediated Induction of Pim 2 Allows Human T Regulatory Cells to Preferentially Expand in Rapamycin. <i>Journal of Immunology</i> , 2008, 180, 5794-5798.	0.8	167
41	Cytokine stimulation of aerobic glycolysis in hematopoietic cells exceeds proliferative demand. <i>FASEB Journal</i> , 2004, 18, 1303-1305.	0.5	157
42	CD28 Costimulation Is Essential for Human T Regulatory Expansion and Function. <i>Journal of Immunology</i> , 2008, 181, 2855-2868.	0.8	152
43	CD28 and Inducible Costimulatory Protein Src Homology 2 Binding Domains Show Distinct Regulation of Phosphatidylinositol 3-Kinase, Bcl-xL, and IL-2 Expression in Primary Human CD4 T Lymphocytes. <i>Journal of Immunology</i> , 2003, 171, 166-174.	0.8	146
44	Molecular analysis of G1B and G3A IFN $\gamma$ mutants reveals that defects in CIITA or RFX result in defective class II MHC and li gene induction. <i>Immunity</i> , 1994, 1, 687-697.	14.3	136
45	Simultaneous zinc-finger nuclease editing of the HIV coreceptors ccr5 and cxcr4 protects CD4+ T cells from HIV-1 infection. <i>Blood</i> , 2014, 123, 61-69.	1.4	135
46	Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells. <i>Blood</i> , 2008, 112, 2847-2857.	1.4	134
47	Steric Shielding of Surface Epitopes and Impaired Immune Recognition Induced by the Ebola Virus Glycoprotein. <i>PLoS Pathogens</i> , 2010, 6, e1001098.	4.7	132
48	Engineering HIV-Resistant Human CD4+ T Cells with CXCR4-Specific Zinc-Finger Nucleases. <i>PLoS Pathogens</i> , 2011, 7, e1002020.	4.7	130
49	FOXP3 is a homo-oligomer and a component of a supramolecular regulatory complex disabled in the human XLAAD/IPEX autoimmune disease. <i>International Immunology</i> , 2007, 19, 825-835.	4.0	124
50	Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs. <i>Clinical Immunology</i> , 2010, 136, 348-363.	3.2	124
51	Retinoic Acid and Rapamycin Differentially Affect and Synergistically Promote the Ex Vivo Expansion of Natural Human T Regulatory Cells. <i>PLoS ONE</i> , 2011, 6, e15868.	2.5	118
52	ICOS Costimulation Requires IL-2 and Can Be Prevented by CTLA-4 Engagement. <i>Journal of Immunology</i> , 2001, 166, 4943-4948.	0.8	111
53	Efficient Clinical Scale Gene Modification via Zinc Finger Nuclease–Targeted Disruption of the HIV Co-receptor CCR5. <i>Human Gene Therapy</i> , 2013, 24, 245-258.	2.7	110
54	Large-Scale Production of CD4+ T Cells from HIV-1-Infected Donors After CD3/CD28 Costimulation*. <i>Stem Cells and Development</i> , 1998, 7, 437-448.	1.0	107

#	ARTICLE	IF	CITATIONS
55	Folate Receptor Alpha and Caveolae Are Not Required for Ebola Virus Glycoprotein-Mediated Viral Infection. <i>Journal of Virology</i> , 2003, 77, 13433-13438.	3.4	106
56	Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor. <i>PLoS Pathogens</i> , 2017, 13, e1006613.	4.7	106
57	Generation of human islet-specific regulatory T cells by TCR gene transfer. <i>Journal of Autoimmunity</i> , 2017, 79, 63-73.	6.5	102
58	Recommendations for measuring HIV reservoir size in cure-directed clinical trials. <i>Nature Medicine</i> , 2020, 26, 1339-1350.	30.7	96
59	Clinical perspectives for regulatory T cells in transplantation tolerance. <i>Seminars in Immunology</i> , 2011, 23, 462-468.	5.6	95
60	Prostaglandin E2 Impairs CD4+ T Cell Activation by Inhibition of Ick: Implications in Hodgkin's Lymphoma. <i>Cancer Research</i> , 2006, 66, 1114-1122.	0.9	93
61	cIAP2 is a ubiquitin protein ligase for BCL10 and is dysregulated in mucosa-associated lymphoid tissue lymphomas. <i>Journal of Clinical Investigation</i> , 2005, 116, 174-181.	8.2	91
62	Productive Infection of Neonatal CD8+ T Lymphocytes by HIV-1. <i>Journal of Experimental Medicine</i> , 1998, 187, 1139-1144.	8.5	89
63	A Cell-Based Artificial Antigen-Presenting Cell Coated with Anti-CD3 and CD28 Antibodies Enables Rapid Expansion and Long-Term Growth of CD4 T Lymphocytes. <i>Clinical Immunology</i> , 2002, 105, 259-272.	3.2	84
64	Regulatory T Cells and Human Myeloid Dendritic Cells Promote Tolerance via Programmed Death Ligand-1. <i>PLoS Biology</i> , 2010, 8, e1000302.	5.6	81
65	Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality. <i>Journal of Clinical Investigation</i> , 2016, 126, 2642-2660.	8.2	81
66	B and T Lymphocyte Attenuator-Mediated Signal Transduction Provides a Potent Inhibitory Signal to Primary Human CD4 T Cells That Can Be Initiated by Multiple Phosphotyrosine Motifs. <i>Journal of Immunology</i> , 2006, 176, 6603-6614.	0.8	76
67	RNA fingerprints provide direct evidence for the inhibitory role of TGF $\beta$ 2 and PD-1 on CD4+ T cells in Hodgkin lymphoma. <i>Blood</i> , 2007, 110, 3226-3233.	1.4	76
68	Naïve and Memory CD4 T Cells Differ in Their Susceptibilities to Human Immunodeficiency Virus Type 1 Infection following CD28 Costimulation: Implications for Transmission and Pathogenesis. <i>Journal of Virology</i> , 1998, 72, 8273-8280.	3.4	71
69	HLA tetramer-based artificial antigen-presenting cells for stimulation of CD4+ T cells. <i>Clinical Immunology</i> , 2003, 106, 16-22.	3.2	70
70	miR-146b antagomir-treated human Tregs acquire increased GVHD inhibitory potency. <i>Blood</i> , 2016, 128, 1424-1435.	1.4	70
71	The Paracaspase MALT1 Controls Caspase-8 Activation during Lymphocyte Proliferation. <i>Molecular Cell</i> , 2008, 31, 415-421.	9.7	67
72	Combination Checkpoint Blockade "Taking Melanoma Immunotherapy to the Next Level. <i>New England Journal of Medicine</i> , 2013, 369, 187-189.	27.0	65

#	ARTICLE	IF	CITATIONS
73	Mode of Transmission Affects the Sensitivity of Human Immunodeficiency Virus Type 1 to Restriction by Rhesus TRIM5 $\beta$ . Journal of Virology, 2008, 82, 11117-11128.	3.4	63
74	Dual CD4-based CAR T cells with distinct costimulatory domains mitigate HIV pathogenesis in vivo. Nature Medicine, 2020, 26, 1776-1787.	30.7	63
75	Genetic engineering of T cells for immunotherapy. Nature Reviews Genetics, 2021, 22, 427-447.	16.3	63
76	Genetic engineering of T cells for adoptive immunotherapy. Immunologic Research, 2008, 42, 166-181.	2.9	59
77	Human CD8+ T cells do not require the polarization of lipid rafts for activation and proliferation. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 15006-15011.	7.1	52
78	Addition of Deoxynucleosides Enhances Human Immunodeficiency Virus Type 1 Integration and 2LTR Formation in Resting CD4 <sup>+</sup> T Cells. Journal of Virology, 2007, 81, 13938-13942.	3.4	52
79	Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes. Journal of Translational Medicine, 2011, 9, 131.	4.4	52
80	CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication. Journal of Clinical Investigation, 2021, 131, .	8.2	52
81	Modulation of Susceptibility to HIV-1 Infection by the Cytotoxic T Lymphocyte Antigen 4 Costimulatory Molecule. Journal of Experimental Medicine, 2000, 191, 1987-1998.	8.5	51
82	TCR affinity and specificity requirements for human regulatory T-cell function. Blood, 2012, 119, 3420-3430.	1.4	49
83	Distinct Effects of IL-18 on the Engraftment and Function of Human Effector CD8+ T Cells and Regulatory T Cells. PLoS ONE, 2008, 3, e3289.	2.5	48
84	Adoptive immunotherapy: good habits instilled at youth have long-term benefits. Immunologic Research, 2008, 42, 182-196.	2.9	47
85	Extensive Replicative Capacity of Human Central Memory T Cells. Journal of Immunology, 2004, 172, 6675-6683.	0.8	46
86	Differential Reliance on Lipid Metabolism as a Salvage Pathway Underlies Functional Differences of T Cell Subsets in Poor Nutrient Environments. Cell Reports, 2018, 23, 741-755.	6.4	45
87	The Battle over mTOR: An Emerging Theatre in Host-Pathogen Immunity. PLoS Pathogens, 2012, 8, e1002894.	4.7	44
88	Engineering T Cells to Functionally Cure HIV-1 Infection. Molecular Therapy, 2015, 23, 1149-1159.	8.2	43
89	Potent and Broad Inhibition of HIV-1 by a Peptide from the gp41 Heptad Repeat-2 Domain Conjugated to the CXCR4 Amino Terminus. PLoS Pathogens, 2016, 12, e1005983.	4.7	43
90	MHC Class II Gene Silencing in Trophoblast Cells Is Caused by Inhibition of CIITA Expression. American Journal of Reproductive Immunology, 1998, 40, 385-394.	1.2	42

#	ARTICLE	IF	CITATIONS
91	Optimization of cGMP purification and expansion of umbilical cord bloodâ€‘derived T-regulatory cells in support of first-in-human clinical trials. <i>Cytotherapy</i> , 2017, 19, 250-262.	0.7	41
92	Selective reactivation of STING signaling to target Merkel cell carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 13730-13739.	7.1	39
93	Improved Expansion and InÂVivo Function of Patient T Cells by a Serum-free Medium. <i>Molecular Therapy - Methods and Clinical Development</i> , 2018, 8, 65-74.	4.1	37
94	Robust expansion of HIV CAR T cells following antigen boosting in ART-suppressed nonhuman primates. <i>Blood</i> , 2020, 136, 1722-1734.	1.4	37
95	Signalling to suit function: tailoring phosphoinositide 3-kinase during T-cell activation. <i>Trends in Immunology</i> , 2007, 28, 161-168.	6.8	36
96	Ligation of CD28 by Its Natural Ligand CD86 in the Absence of TCR Stimulation Induces Lipid Raft Polarization in Human CD4 T Cells. <i>Journal of Immunology</i> , 2005, 175, 7848-7854.	0.8	33
97	Stabilized Human TRIM5Î± Protects Human T Cells From HIV-1 Infection. <i>Molecular Therapy</i> , 2014, 22, 1084-1095.	8.2	33
98	Suppression of HIV-1 infection in primary CD4 T cells transduced with a self-inactivating lentiviral vector encoding a membrane expressed gp41-derived fusion inhibitor. <i>Clinical Immunology</i> , 2005, 115, 26-32.	3.2	32
99	The road to recovery: translating PD-1 biology into clinical benefit. <i>Trends in Immunology</i> , 2007, 28, 48-50.	6.8	32
100	The Potent Oncogene NPM-ALK Mediates Malignant Transformation of Normal Human CD4+ T Lymphocytes. <i>American Journal of Pathology</i> , 2013, 183, 1971-1980.	3.8	32
101	Cutting Edge: A Novel, Human-Specific Interacting Protein Couples FOXP3 to a Chromatin-Remodeling Complex That Contains KAP1/TRIM28. <i>Journal of Immunology</i> , 2013, 190, 4470-4473.	0.8	32
102	Topoisomerase inhibitors modulate expression of melanocytic antigens and enhance T cell recognition of tumor cells. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 133-144.	4.2	29
103	HIV-Resistant and HIV-Specific CAR-Modified CD4+ T Cells Mitigate HIV Disease Progression and Confer CD4+ T Cell Help InÂVivo. <i>Molecular Therapy</i> , 2020, 28, 1585-1599.	8.2	29
104	Umbilical Cord Blood Xenografts in Immunodeficient Mice Reveal That T Cells Enhance Hematopoietic Engraftment Beyond Overcoming Immune Barriers by Stimulating Stem Cell Differentiation. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1135-1144.	2.0	27
105	Cutaneous T Cell Lymphoma Expresses Immunosuppressive CD80 (B7-1) Cell Surface Protein in a STAT5-Dependent Manner. <i>Journal of Immunology</i> , 2014, 192, 2913-2919.	0.8	27
106	In Vitro Induction of Human Regulatory T Cells Using Conditions of Low Tryptophan Plus Kynurenines. <i>American Journal of Transplantation</i> , 2017, 17, 3098-3113.	4.7	27
107	CAR Talk: How Cancer-Specific CAR T Cells Can Instruct How to Build CAR T Cells to Cure HIV. <i>Frontiers in Immunology</i> , 2019, 10, 2310.	4.8	26
108	Cell-Mediated Immunity to Target the Persistent Human Immunodeficiency Virus Reservoir. <i>Journal of Infectious Diseases</i> , 2017, 215, S160-S171.	4.0	24



#	ARTICLE	IF	CITATIONS
109	The role of co-stimulation in regulation of chemokine receptor expression and HIV-1 infection in primary T lymphocytes. <i>Seminars in Immunology</i> , 1998, 10, 195-202.	5.6	22
110	Kruppel-like Factor 2 Modulates CCR5 Expression and Susceptibility to HIV-1 Infection. <i>Journal of Immunology</i> , 2012, 189, 3815-3821.	0.8	22
111	Low-density PD-1 expression on resting human natural killer cells is functional and upregulated after transplantation. <i>Blood Advances</i> , 2021, 5, 1069-1080.	5.2	20
112	HIV Sequence Variation Associated With env Antisense Adoptive T-cell Therapy in the hNSG Mouse Model. <i>Molecular Therapy</i> , 2010, 18, 803-811.	8.2	19
113	Translating In Vitro T Cell Metabolic Findings to In Vivo Tumor Models of Nutrient Competition. <i>Cell Metabolism</i> , 2018, 28, 190-195.	16.2	19
114	Challenges and Opportunities of Using Adoptive T-Cell Therapy as Part of an HIV Cure Strategy. <i>Journal of Infectious Diseases</i> , 2021, 223, S38-S45.	4.0	15
115	NPM1-ALK-Induced Reprogramming of Mature TCR-Stimulated T Cells Results in Dedifferentiation and Malignant Transformation. <i>Cancer Research</i> , 2021, 81, 3241-3254.	0.9	10
116	Influenza Virus Upregulates CXCR4 Expression in CD4+ Cells. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 19-25.	1.1	9
117	CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms.. <i>Blood</i> , 2004, 104, 2657-2657.	1.4	9
118	How to kill Treg cells for immunotherapy. <i>Nature Cancer</i> , 2020, 1, 1134-1135.	13.2	7
119	Trafficking and persistence of alloantigen-specific chimeric antigen receptor regulatory T cells in Cynomolgus macaque. <i>Cell Reports Medicine</i> , 2022, 3, 100614.	6.5	7
120	Characterization of CAR T cell expansion and cytotoxic potential during Ex Vivo manufacturing using image-based cytometry. <i>Journal of Immunological Methods</i> , 2020, 484-485, 112830.	1.4	6
121	Engineering T cells to survive and thrive in the hostile tumor microenvironment. <i>Current Opinion in Biomedical Engineering</i> , 2022, 21, 100360.	3.4	5
122	Modulation of Hepatitis C Virus-Specific CD8 Effector T-Cell Function with Antiviral Effect in Infectious Hepatitis C Virus Coculture Model. <i>Journal of Virology</i> , 2017, 91, .	3.4	4
123	Response from Carroll et al.. <i>Trends in Microbiology</i> , 1997, 5, 302-303.	7.7	3
124	The Human CD8 $\beta$ M-4 Isoform Dominant in Effector Memory T Cells Has Distinct Cytoplasmic Motifs That Confer Unique Properties. <i>PLoS ONE</i> , 2013, 8, e59374.	2.5	3
125	Are affinity-enhanced T cells the future of HIV therapy?. <i>HIV Therapy</i> , 2009, 3, 105-108.	0.6	1
126	Quantitation of HIV-1 Entry Cofactor Expression. , 1999, 17, 219-226.		0



#	ARTICLE	IF	CITATIONS
127	Genetically Modified T Cells for Human Gene Therapy. , 0, , 193-205.		0
128	Ultrasensitive antigen density discrimination by synNotch. Cell Research, 2021, 31, 725-726.	12.0	0
129	Engineered ovarian cancer artificial antigen presenting cells (aAPCs) support CD8+T cells growth and function. FASEB Journal, 2008, 22, 519-519.	0.5	0